Esperion Therapeutics, Inc.
Financial highlights
| Metric | FY December 31, 2025 | FY December 31, 2024 | FY December 31, 2023 | FY December 31, 2022 | FY December 31, 2021 |
|---|---|---|---|---|---|
| Revenue | $403.1M | $332.3M | $116.3M | $75.5M | $78.4M |
| Operating income | $60.3M | $54.4M | -$155.6M | -$179.5M | -$226.7M |
| Operating expenses | $342.9M | $277.9M | $271.9M | $255.0M | $305.2M |
| Cash from operations | -$13.1M | -$23.7M | -$135.5M | -$174.8M | -$263.8M |
| Capital expenditure | $0 | $317,000 | $0 | $0 | $0 |
| Free cash flow | -$13.1M | -$24.0M | -$135.5M | -$174.8M | -$263.8M |
| Share repurchases | — | — | — | — | $0 |
| Impairments | $0 | $0 | $0 | $0 | $0 |
| Total assets | $465.9M | $343.8M | $205.8M | $247.9M | $381.6M |
| Total liabilities | $767.9M | $732.5M | $660.8M | $571.7M | $578.5M |
Shares outstanding 257.4M · Free float 97.2%
Annual filing data through FY ended December 31, 2025; float as of July 13, 2026.